Login
$ALLO
$0.81 +$0.00 (0.37%) After hours

$ALLO SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
06 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., November 5, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, tod...

27 Oct 2026 SCHEDULE 13G/A
23 Oct 2026 Form 4: Parker Geoffrey M., CHIEF FINANCIAL OFFICER

Sold 36,342 shares ($48.7K)

21 Oct 2026 144
30 Sep 2026 SCHEDULE 13D/A
02 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

25 Aug 2026 Form 4: Douglas Earl Martin, SVP, General Counsel

Sold 29,697 shares ($63K)

21 Aug 2026 144
20 Aug 2026 EFFECT
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 S-3
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

SOUTH SAN FRANCISCO, Calif., August 12, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, toda...

07 Aug 2026 SCHEDULE 13G/A
07 Aug 2026 SCHEDULE 13G
06 Jul 2026 Form 4: Roberts Zachary, President and CEO

Granted 134,530 Restricted Stock Unit · Granted 476,190 Stock Option (Right to buy)

23 Jun 2026 Form 4: Kazam Joshua A, Director

Received 47,700 shares by exercise or conversion · Granted 95,400 Restricted Stock Unit

23 Jun 2026 Form 4: Messemer Deborah M., Director

Granted 95,400 Restricted Stock Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support